[ CAS No. 111248-89-6 ] {[proInfo.proName]}

Name: 111248-89-6|1,3-Dihydrobenzo[c]isothiazole 2,2-dioxide|97%
Brand: Ambeed
SKU: A185260
Price: 66.0 USD
Availability: InStock
Rating: 99 (27 reviews)

,{[proInfo.pro_purity]}

Cat. No.: {[proInfo.prAm]}

DV 2D 3D

3d Animation Molecule Structure of 111248-89-6

Structure of 111248-89-6 * Storage: {[proInfo.prStorage]}

Cart0 Add to My Favorites Add to My Favorites Bulk Inquiry Inquiry Add To Cart

Search after Editing

* Storage: {[proInfo.prStorage]}

For Research Only 110K+ Compounds Competitive Price 1-2 Day Shipping

Quality Control of [ 111248-89-6 ]

COA NMR CNMR HPLC LC-MS

Related Doc. of [ 111248-89-6 ]

SDS Specification

Alternatived Products of [ 111248-89-6 ]

Product Details of [ 111248-89-6 ]

CAS No. :	111248-89-6	MDL No. :	MFCD11043148
Formula :	C₇H₇NO₂S	Boiling Point :	-
Linear Structure Formula :	-	InChI Key :	OJWMDOIYUCEXNF-UHFFFAOYSA-N
M.W :	169.20	Pubchem ID :	15536009
Synonyms :

Calculated chemistry of [ 111248-89-6 ]

Physicochemical Properties

Num. heavy atoms :	11
Num. arom. heavy atoms :	6
Fraction Csp3 :	0.14
Num. rotatable bonds :	0
Num. H-bond acceptors :	2.0
Num. H-bond donors :	1.0
Molar Refractivity :	45.69
TPSA :	54.55 Å²

Pharmacokinetics

GI absorption :	High
BBB permeant :	Yes
P-gp substrate :	No
CYP1A2 inhibitor :	No
CYP2C19 inhibitor :	No
CYP2C9 inhibitor :	No
CYP2D6 inhibitor :	No
CYP3A4 inhibitor :	No
Log Kp (skin permeation) :	-7.01 cm/s

Lipophilicity

Log Po/w (iLOGP) :	0.86
Log Po/w (XLOGP3) :	0.46
Log Po/w (WLOGP) :	1.3
Log Po/w (MLOGP) :	0.24
Log Po/w (SILICOS-IT) :	0.89
Consensus Log Po/w :	0.75

Druglikeness

Lipinski :	0.0
Ghose :	None
Veber :	0.0
Egan :	0.0
Muegge :	1.0
Bioavailability Score :	0.55

Water Solubility

Log S (ESOL) :	-1.58
Solubility :	4.43 mg/ml ; 0.0262 mol/l
Class :	Very soluble
Log S (Ali) :	-1.17
Solubility :	11.3 mg/ml ; 0.067 mol/l
Class :	Very soluble
Log S (SILICOS-IT) :	-2.64
Solubility :	0.388 mg/ml ; 0.00229 mol/l
Class :	Soluble

Medicinal Chemistry

PAINS :	0.0 alert
Brenk :	0.0 alert
Leadlikeness :	1.0
Synthetic accessibility :	2.39

Safety of [ 111248-89-6 ]

Signal Word:	Warning	Class:	N/A
Precautionary Statements:	P261-P305+P351+P338	UN#:	N/A
Hazard Statements:	H302-H315-H319-H335	Packing Group:	N/A
GHS Pictogram:

Application In Synthesis of [ 111248-89-6 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

Upstream synthesis route of [ 111248-89-6 ]
Downstream synthetic route of [ 111248-89-6 ]

[ 111248-89-6 ] Synthesis Path-Upstream 1~8

1
[ 89665-79-2 ]
[ 111248-89-6 ]

Yield	Reaction Conditions	Operation in experiment
80%	With tris-(dibenzylideneacetone)dipalladium⁽⁰⁾; potassium carbonate; tert-butyl XPhos In tetrahydrofuran at 80℃; for 13 h; Microwave irradiation	(2-Chlorophenyl)methanesulfonamide (450 mg, 2.19 mmol), tris(dibenzylideneacetone) dipalladium (100 mg, 0.109 mmol), 2-di-tert-butylphosphino-2',4',6'-tri-isopropylbiphenyl (186 mg, 0.438 mmol) and potassium carbonate (605 mg, 4.38 mmol) were loaded in a microwave vial and THF (8.8 mL) was added. The reaction mixture was stirred at 80 °C for 13 h before being quenched with a saturated solution of ammonium chloride. The solvent was then evaporated and the residue was purified by column chromatography (cyclohexane/acetone) to afford the title compound as a white solid (296 mg, 80percent). ¹H NMR (500 MHz, CDCl₃) ppm = 7.31 - 7.26 (m, 1 H), 7.26 - 7.23 (m, 1 H), 7.07 (td, J=7.6, 0.9, 1 H), 6.90 (d, J=8.0, 1 H), 6.48 (bs, 1 H), 4.39 (s, 2H). Rt = 1.69 min (HPLC method C).
80%	With tris-(dibenzylideneacetone)dipalladium⁽⁰⁾; potassium carbonate; tert-butyl XPhos In tetrahydrofuran at 80℃; for 13 h;	4b. I ,3-Dihydrobenzo[c]isothiazole 2,2-dioxide (2-Chlorophenyl)methanesulfonamide (450 mg, 2.19 mmol),tris(dibenzylideneacetone) dipalladium (100 mg, 0.109 mmol), 2-di-tert butylphosphino-2’,4’,6’-tri-isopropylbiphenyl (186 mg, 0.438 mmol) and potassium carbonate (605 mg, 4.38 mmol) were loaded in a microwave vial and THF (8.8 mL) wasadded. The reaction mixture was stirred at 80 °C for 13 hr before being quenched with a sat. NH4CI solution. The solvent was then evaporated and the residue was purified by column chromatography (CyHex/acetone) to afford the title compound as a white solid (296 mg, 80percent). 1H NMR (500 MHz, CDCI3) ppm = 7.31 - 7.26 (m, 1H), 7.26 - 7.23 (m, 1H), 7.07 (td, J=7.6, 0.9, IH), 6.90 (d, J=8.0, IH), 6.48 (bs, IH), 4.39 (s, 2H); Rt = 1.69mm (HPLC method F).
80%	With tris-(dibenzylideneacetone)dipalladium⁽⁰⁾; potassium carbonate; tert-butyl XPhos In tetrahydrofuran at 80℃; for 13 h;	b. 1,3-Dihydrobenzo[c]isothiazole 2,2-dioxide (2-Chlorophenyl)methanesulfonamide (450 mg, 2.19 mmol), tris(dibenzylideneacetone)dipalladium (100 mg, 0.109 mmol), 2-di-tert-butylphosphino-2',4',6'-tri-isopropylbiphenyl (186 mg, 0.438 mmol) and potassium carbonate (605 mg, 4.38 mmol) were loaded in a microwave vial and THF (8.8 mL) was added. The reaction mixture was stirred at 80° C. for 13 h before being quenched with a sat. NH₄Cl solution. The solvent was then evaporated and the residue was purified by column chromatography (CyHex/acetone) to afford the title compound as a white solid (296 mg, 80percent).

Reference： [1] Patent: WO2014/63778, 2014, A1, . Location in patent: Page/Page column 43
[2] Patent: WO2015/144290, 2015, A1, . Location in patent: Page/Page column 87
[3] Patent: US2016/16951, 2016, A1, . Location in patent: Paragraph 0245; 0247
[4] Journal of Medicinal Chemistry, 2016, vol. 59, # 3, p. 1078 - 1101
[5] Journal of Heterocyclic Chemistry, 1986, vol. 23, p. 1645 - 1649
[6] Patent: WO2005/63690, 2005, A1, . Location in patent: Page/Page column 23

2
[ 24974-75-2 ]
[ 111248-89-6 ]

Yield	Reaction Conditions	Operation in experiment
6.5%	Stage #1: With tin(ll) chloride In ethyl acetate at 70℃; Stage #2: With triethylamine In dichloromethane at 20℃;	Preparation 17 1,3-Dihydrobenzo[c]isothiazole 2,2-dioxide The title compound was prepared using the method described in WO 98/32438 A1. To a solution of 2-nitro-alpha-toluenesulfonyl chloride (5.1 g, 21.6 mmol) in anhydrous ethyl acetate (250 mL) was added tin(II) chloride (19.3 g, 86 mmol). The reaction was stirred overnight at 70° C., then poured onto ice and neutralized with saturated aqueous sodium bicarbonate. The solution was filtered through Celite, extracted with ethyl acetate, and the organic layer concentrated. To the crude residue was added anhydrous methylene chloride (200 mL) and triethylamine (5 mL). The solution was stirred overnight at room temperature and concentrated under reduced pressure. The product was obtained by silica gel column chromatography (30-100percent ethyl acetate in hexanes) followed by recrystallization from methylene chloride/hexanes to give a white solid. (0.24 g, 6.5percent). ¹H NMR (CDCl₃, 300 MHz) δ 7.30-7.22 (m, 2H), 7.07-7.02 (t, 1H, J=7.4 Hz), 6.89-6.86 (dd, 1H, J=0.6, 8.1 Hz), 6.66 (br s, 1H), 4.39 (s, 1H).

Reference： [1] Patent: US2013/303524, 2013, A1, . Location in patent: Paragraph 0270-0271

3
[ 111249-29-7 ]
[ 111248-89-6 ]

Reference： [1] Journal of Heterocyclic Chemistry, 1986, vol. 23, p. 1645 - 1649
[2] Patent: WO2013/131408, 2013, A1, . Location in patent: Page/Page column 81

4
[ 77421-13-7 ]
[ 111248-89-6 ]

Reference： [1] Patent: WO2014/63778, 2014, A1,
[2] Patent: WO2015/144290, 2015, A1,
[3] Patent: US2016/16951, 2016, A1,
[4] Journal of Medicinal Chemistry, 2016, vol. 59, # 3, p. 1078 - 1101

5
[ 3958-60-9 ]
[ 111248-89-6 ]

Reference： [1] Patent: WO2013/131408, 2013, A1,

6
[ 41345-06-6 ]
[ 111248-89-6 ]

Reference： [1] Patent: WO2013/131408, 2013, A1,

7
[ 6961-82-6 ]
[ 111248-89-6 ]

Reference： [1] Patent: US6339098, 2002, B1, . Location in patent: Page column 10

8
[ 20474-37-7 ]
[ 111248-89-6 ]
[ 2116-62-3 ]
[ 103-29-7 ]

Reference： [1] Heterocycles, 1987, vol. 26, # 9, p. 2327 - 2330

[ 111248-89-6 ] Synthesis Path-Downstream 1~88

1
[ 25145-43-1 ]
[ 111248-89-6 ]
[ 111249-10-6 ]

Reference： [1]Journal of Heterocyclic Chemistry,1986,vol. 23,p. 1645 - 1649

2
[ 20474-37-7 ]
[ 111248-89-6 ]
[ 2116-62-3 ]
[ 103-29-7 ]

Reference： [1]Heterocycles,1987,vol. 26,p. 2327 - 2330

3
[ 89665-79-2 ]
[ 111248-89-6 ]

Yield	Reaction Conditions	Operation in experiment
80%	With tris-(dibenzylideneacetone)dipalladium(0); potassium carbonate; tert-butyl XPhos; In tetrahydrofuran; at 80℃; for 13h;Microwave irradiation;	(2-Chlorophenyl)methanesulfonamide (450 mg, 2.19 mmol), tris(dibenzylideneacetone) dipalladium (100 mg, 0.109 mmol), 2-di-tert-butylphosphino-2',4',6'-tri-isopropylbiphenyl (186 mg, 0.438 mmol) and potassium carbonate (605 mg, 4.38 mmol) were loaded in a microwave vial and THF (8.8 mL) was added. The reaction mixture was stirred at 80 C for 13 h before being quenched with a saturated solution of ammonium chloride. The solvent was then evaporated and the residue was purified by column chromatography (cyclohexane/acetone) to afford the title compound as a white solid (296 mg, 80%). 1H NMR (500 MHz, CDCl3) ppm = 7.31 - 7.26 (m, 1 H), 7.26 - 7.23 (m, 1 H), 7.07 (td, J=7.6, 0.9, 1 H), 6.90 (d, J=8.0, 1 H), 6.48 (bs, 1 H), 4.39 (s, 2H). Rt = 1.69 min (HPLC method C).
80%	With tris-(dibenzylideneacetone)dipalladium(0); potassium carbonate; tert-butyl XPhos; In tetrahydrofuran; at 80℃; for 13h;	4b. I ,3-Dihydrobenzo[c]isothiazole 2,2-dioxide (2-Chlorophenyl)methanesulfonamide (450 mg, 2.19 mmol),tris(dibenzylideneacetone) dipalladium (100 mg, 0.109 mmol), 2-di-tert butylphosphino-2?,4?,6?-tri-isopropylbiphenyl (186 mg, 0.438 mmol) and potassium carbonate (605 mg, 4.38 mmol) were loaded in a microwave vial and THF (8.8 mL) wasadded. The reaction mixture was stirred at 80 C for 13 hr before being quenched with a sat. NH4CI solution. The solvent was then evaporated and the residue was purified by column chromatography (CyHex/acetone) to afford the title compound as a white solid (296 mg, 80%). 1H NMR (500 MHz, CDCI3) ppm = 7.31 - 7.26 (m, 1H), 7.26 - 7.23 (m, 1H), 7.07 (td, J=7.6, 0.9, IH), 6.90 (d, J=8.0, IH), 6.48 (bs, IH), 4.39 (s, 2H); Rt = 1.69mm (HPLC method F).
80%	With tris-(dibenzylideneacetone)dipalladium(0); potassium carbonate; tert-butyl XPhos; In tetrahydrofuran; at 80℃; for 13h;	b. 1,3-Dihydrobenzo[c]isothiazole 2,2-dioxide (2-Chlorophenyl)methanesulfonamide (450 mg, 2.19 mmol), tris(dibenzylideneacetone)dipalladium (100 mg, 0.109 mmol), 2-di-tert-butylphosphino-2',4',6'-tri-isopropylbiphenyl (186 mg, 0.438 mmol) and potassium carbonate (605 mg, 4.38 mmol) were loaded in a microwave vial and THF (8.8 mL) was added. The reaction mixture was stirred at 80 C. for 13 h before being quenched with a sat. NH4Cl solution. The solvent was then evaporated and the residue was purified by column chromatography (CyHex/acetone) to afford the title compound as a white solid (296 mg, 80%).

Reference： [1]Patent: WO2014/63778,2014,A1 .Location in patent: Page/Page column 43
[2]Patent: WO2015/144290,2015,A1 .Location in patent: Page/Page column 87
[3]Patent: US2016/16951,2016,A1 .Location in patent: Paragraph 0245; 0247
[4]Journal of Medicinal Chemistry,2016,vol. 59,p. 1078 - 1101
[5]Journal of Heterocyclic Chemistry,1986,vol. 23,p. 1645 - 1649
[6]Patent: WO2005/63690,2005,A1 .Location in patent: Page/Page column 23

4
[ 541-41-3 ]
[ 111248-89-6 ]
[ 111249-03-7 ]

Reference： [1]Journal of Heterocyclic Chemistry,1986,vol. 23,p. 1645 - 1649

5
[ 609-65-4 ]
[ 111248-89-6 ]
[ 111249-12-8 ]

Reference： [1]Journal of Heterocyclic Chemistry,1986,vol. 23,p. 1645 - 1649

6
[ 111248-89-6 ]
[ 111310-59-9 ]

Reference： [1]Journal of Heterocyclic Chemistry,1986,vol. 23,p. 1645 - 1649

7
[ 111248-89-6 ]
[ 111248-92-1 ]

Yield	Reaction Conditions	Operation in experiment
		4f. 5-bromo-1 ,3-dihydrobenzo[c]isothiazole 2,2-dioxide 1,3-Dihydro-benzo[c]isothiazole 22-dioxide (0.50 g, 3.14 mmol, 1.00 eq.)was solubilized in acetic acid (5 mL) at RT under nitrogen atmosphere.Bromine (0.45 g, 3.14 mmol, 1.00 eq.) in acetic acid (5 mL) was added dropwise over 5 minutes and the reaction mixture was stirred for 0.5 h. Potassium, acetate (0.28 g, 3.14 mmol, 1.00 eq.) was added and the reaction mixture was concentrated to dryness. The residue was taken in 2 % NaHCO3 solution and stirred for 10 minutes. This solution wasacidified to pH 2 using conc. HCI (2.5 mL) and extracted with MTBE (50 mL). The MTBE layer was washed with water (50 mL), brine solution (25 mL), dried over Na2SO4 and concentrated to get the crude product as brown solid. The crude product was triturated with petroleum ether (10 mL), filtered to a light brown solid (HPLC purity app. 86 %) which was further purified by column chromatography using 60-1 20 mesh silica gel, 15 %ethyl acetate in petroleum ether as eluent to get a yellow solid (HPLC purity app.90 %). The resulting product was then triturated with ethanol (5 mL), filtered and dried to get the title compounds as light yellow solid (0.35 g, 47.7 %, 94% purity).
	With bromine; acetic acid; for 0.583333h;Inert atmosphere;	f. 5-bromo-<strong>[111248-89-6]1,3-dihydrobenzo[c]isothiazole 2,2-dioxide</strong> 1,3-Dihydro-benzo[c]isothiazole 2,2-dioxide (0.50 g, 3.14 mmol, 1.00 eq.) was solubilized in acetic acid (5 mL) at rt under nitrogen atmosphere. Bromine (0.45 g, 3.14 mmol, 1.00 eq.) in acetic acid (5 mL) was added dropwise over 5 minutes and the reaction mixture was stirred for 0.5 h. Potassium acetate (0.28 g, 3.14 mmol, 1.00 eq.) was added and the reaction mixture was concentrated to dryness. The residue was taken in 2% NaHCO3 solution and stirred for 10 minutes. This solution was acidified to pH 2 using conc. HCl (2.5 mL) and extracted with MTBE (50 mL). The MTBE layer was washed with water (50 mL), brine solution (25 mL), dried over Na2SO4 and concentrated to get the crude product as brown solid. The crude product was triturated with petroleum ether (10 mL), filtered to a light brown solid (HPLC purity app. 86%) which was further purified by column chromatography using 60-120 mesh silica gel, 15% ethyl acetate in petroleum ether as eluent to get a yellow solid (HPLC purity app. 90%). The resulting product was then triturated with ethanol (5 mL), filtered and dried to get the title compounds as light yellow solid (0.35 g, 47.7%, 94% purity).

Reference： [1]Patent: WO2013/131408,2013,A1 .Location in patent: Page/Page column 81
[2]Journal of Heterocyclic Chemistry,1986,vol. 23,p. 1645 - 1649
[3]Patent: WO2015/144290,2015,A1 .Location in patent: Page/Page column 88; 89
[4]Patent: US2016/16951,2016,A1 .Location in patent: Paragraph 0245; 0251

8
[ 111248-89-6 ]
[ 111248-94-3 ]
[ 111248-95-4 ]
[ 111248-96-5 ]

Reference： [1]Journal of Heterocyclic Chemistry,1986,vol. 23,p. 1645 - 1649

9
[ 111248-89-6 ]
[ 111248-96-5 ]

Reference： [1]Journal of Heterocyclic Chemistry,1986,vol. 23,p. 1645 - 1649

10
[ 111249-29-7 ]
[ 111248-89-6 ]

Reference： [1]Journal of Heterocyclic Chemistry,1986,vol. 23,p. 1645 - 1649
[2]Patent: WO2013/131408,2013,A1 .Location in patent: Page/Page column 81

11
[ 111248-89-6 ]
[ 98-88-4 ]
[ 111249-11-7 ]

Reference： [1]Journal of Heterocyclic Chemistry,1986,vol. 23,p. 1645 - 1649

12
[ 111248-89-6 ]
[ 122-01-0 ]
[ 111249-13-9 ]

Reference： [1]Journal of Heterocyclic Chemistry,1986,vol. 23,p. 1645 - 1649

13
[ 111248-89-6 ]
[ 105-39-5 ]
[ 111249-23-1 ]

Reference： [1]Journal of Heterocyclic Chemistry,1986,vol. 23,p. 1645 - 1649

14
[ 111248-89-6 ]
[ 107-99-3 ]
[ 32084-03-0 ]

Reference： [1]Journal of Heterocyclic Chemistry,1986,vol. 23,p. 1645 - 1649

15
[ 111248-89-6 ]
[ 75-36-5 ]
[ 111249-08-2 ]

Reference： [1]Journal of Heterocyclic Chemistry,1986,vol. 23,p. 1645 - 1649

16
[ 111248-89-6 ]
[ 79-04-9 ]
[ 111249-09-3 ]

Reference： [1]Journal of Heterocyclic Chemistry,1986,vol. 23,p. 1645 - 1649

17
[ 111248-89-6 ]
[ 98-59-9 ]
[ 111249-21-9 ]

Reference： [1]Journal of Heterocyclic Chemistry,1986,vol. 23,p. 1645 - 1649

18
2-bromo-α-toluenesulfonamide [ No CAS ]
[ 111248-89-6 ]

Reference： [1]Heterocycles,1987,vol. 26,p. 2327 - 2330

19
[ 111248-89-6 ]
[ 74-88-4 ]
[ 24827-66-5 ]

Yield	Reaction Conditions	Operation in experiment
89%	With potassium carbonate; In N,N-dimethyl-formamide; at 20℃; for 6h;	To a suspension of 1 ,3-dihydrobenzo[c]isothiazole-2,2-dioxide (280 mg, 1.655 mmol) and potassium carbonate (229 mg, 1.66 mmol) in DMF (5 mL) was added iodomethane (414 pL, 6.62 mmol). The reaction was stirred for 6 h at RT and was then quenched with a saturated solution of ammonium chloride. The reaction mixture was concentrated and purified by column chromatography (cyclohexane/acetone) to afford the title compound as a white solid (270 mg, 89%). 1H NMR (500 MHz, CDCl3) ppm = 7.37 - 7.32 (m, 1 H), 7.27 - 7.24 (m, 1 H), 7.02 (td, J=7.6, 1.0, 1 H), 6.73 (d, J=8.0, 1 H), 4.34 (s, 2H), 3.14 (s, 3H). Rt = 2.07 min (HPLC method C).
89%	With potassium carbonate; In N,N-dimethyl-formamide; at 20℃; for 6h;	4c. 1-Methyl-i ,3-dihydrobenzo[c]isothiazole-2 ,2-dioxide To a suspension of I ,3-dihydrobenzo[c]isothiazole-2,2-dioxide (280 mg,1.655 mmol) and potassium carbonate (229 mg, 1.66 mmol) in DMF (5 mL) was added iodomethane (414 pL, 6.62 mmol). The reaction was stirred for 6 hr at RT andwas then quenched with a sat. NH4CI solution. The reaction mixture was concentratedand purified by column chromatography (CyHex/acetone) to afford the title compound asa white solid (270 mg, 89%). 1H NMR (500 MHz, CDCI3) ppm = 7.37-7.32 (m, 1H), 7.27-7.24 (m, 1H), 7.02 (td, J=7.6, 1.0, IH), 6.73 (d, J8.0, IH), 4.34 (s, 2H), 3.14 (s, 3H); Rt= 2.07 mm (H PLC method F).
89%	With potassium carbonate; In N,N-dimethyl-formamide; at 20℃; for 6h;	c. 1-Methyl-<strong>[111248-89-6]1,3-dihydrobenzo[c]isothiazole-2,2-dioxide</strong> To a suspension of <strong>[111248-89-6]1,3-dihydrobenzo[c]isothiazole-2,2-dioxide</strong> (280 mg, 1.655 mmol) and potassium carbonate (229 mg, 1.66 mmol) in DMF (5 mL) was added iodomethane (414 muL, 6.62 mmol). The reaction was stirred for 6 h at rt and was then quenched with a sat. NH4Cl solution. The reaction mixture was concentrated and purified by column chromatography (CyHex/acetone) to afford the title compound as a white solid (270 mg, 89%).

Reference： [1]Patent: WO2014/63778,2014,A1 .Location in patent: Page/Page column 43
[2]Patent: WO2015/144290,2015,A1 .Location in patent: Page/Page column 88
[3]Patent: US2016/16951,2016,A1 .Location in patent: Paragraph 0245; 0248
[4]Journal of Medicinal Chemistry,2016,vol. 59,p. 1078 - 1101
[5]Journal of Heterocyclic Chemistry,1986,vol. 23,p. 1645 - 1649

20
[ 111248-89-6 ]
1-{2-[4-(4-chloro-benzyl)-piperazin-1-yl]-ethyl}-1,3-dihydro-benzo[<i>c</i>]isothiazole 2,2-dioxide [ No CAS ]

Reference： [1]Bioorganic and Medicinal Chemistry Letters,2002,vol. 12,p. 3105 - 3109

21
[ 111248-89-6 ]
1-{3-[4-(4-chloro-benzyl)-piperazin-1-yl]-propyl}-1,3-dihydro-benzo[<i>c</i>]isothiazole 2,2-dioxide [ No CAS ]

Reference： [1]Bioorganic and Medicinal Chemistry Letters,2002,vol. 12,p. 3105 - 3109

22
[ 111248-89-6 ]
Sodium; (4S,5R,6S)-3-(2,2-dioxo-2,3-dihydro-2λ⁶-benzo[c]isothiazol-1-ylmethyl)-6-((R)-1-hydroxy-ethyl)-4-methyl-7-oxo-1-aza-bicyclo[3.2.0]hept-2-ene-2-carboxylate [ No CAS ]

Reference： [1]Bioorganic and Medicinal Chemistry Letters,1999,vol. 9,p. 673 - 678

23
sodium 2-bromo-α-toluenesulfonate [ No CAS ]
[ 111248-89-6 ]

Reference： [1]Heterocycles,1987,vol. 26,p. 2327 - 2330

24
[ 111248-89-6 ]
[ 111248-94-3 ]

Reference： [1]Journal of Heterocyclic Chemistry,1986,vol. 23,p. 1645 - 1649

25
[ 111248-89-6 ]
[ 111248-99-8 ]

Reference： [1]Journal of Heterocyclic Chemistry,1986,vol. 23,p. 1645 - 1649

26
[ 111248-89-6 ]
[ 111249-02-6 ]

Reference： [1]Journal of Heterocyclic Chemistry,1986,vol. 23,p. 1645 - 1649

27
[ 111248-89-6 ]
[ 111249-24-2 ]

Reference： [1]Journal of Heterocyclic Chemistry,1986,vol. 23,p. 1645 - 1649

28
[ 111248-89-6 ]
[ 111249-15-1 ]

Reference： [1]Journal of Heterocyclic Chemistry,1986,vol. 23,p. 1645 - 1649

29
[ 111248-89-6 ]
[ 111249-17-3 ]

Reference： [1]Journal of Heterocyclic Chemistry,1986,vol. 23,p. 1645 - 1649

30
[ 111248-89-6 ]
[ 111249-07-1 ]

Reference： [1]Journal of Heterocyclic Chemistry,1986,vol. 23,p. 1645 - 1649

31
[ 111248-89-6 ]
[ 111249-05-9 ]

Reference： [1]Journal of Heterocyclic Chemistry,1986,vol. 23,p. 1645 - 1649

32
[ 111248-89-6 ]
[ 111249-22-0 ]

Reference： [1]Journal of Heterocyclic Chemistry,1986,vol. 23,p. 1645 - 1649

33
[ 111248-89-6 ]
[ 111249-18-4 ]

Reference： [1]Journal of Heterocyclic Chemistry,1986,vol. 23,p. 1645 - 1649
[2]Journal of Heterocyclic Chemistry,1986,vol. 23,p. 1645 - 1649

34
[ 111248-89-6 ]
[ 111249-19-5 ]

Reference： [1]Journal of Heterocyclic Chemistry,1986,vol. 23,p. 1645 - 1649

35
[ 111248-89-6 ]
[ 111248-97-6 ]

Reference： [1]Journal of Heterocyclic Chemistry,1986,vol. 23,p. 1645 - 1649
[2]Journal of Heterocyclic Chemistry,1986,vol. 23,p. 1645 - 1649

36
[ 111248-89-6 ]
[ 111248-98-7 ]

Reference： [1]Journal of Heterocyclic Chemistry,1986,vol. 23,p. 1645 - 1649

37
[ 111248-89-6 ]
[ 111249-06-0 ]

Reference： [1]Journal of Heterocyclic Chemistry,1986,vol. 23,p. 1645 - 1649

38
[ 76513-69-4 ]
[ 111248-89-6 ]
1,3-dihydro-1-(2'-trimethylsilylethoxymethyl)-2,1-benzisothiazoline 2,2-dioxide [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
99%	With N-ethyl-N,N-diisopropylamine; In dichloromethane; at 20℃; for 0.5h;	To 1,3-dihydro-2,1-benzisothiazoline 2,2-dioxide (Chiarino et al, J. Heterocycl. Chem. 23(6), 1645-9, 1986) (0.74 g, 4.4 mmol) in anhydrous dichloromethane (minimum amount) at room temperature was added sequentially N,N-diisopropylethylamine (0.76 mL, 4.4 mmol) and 2-(trimethylsilyl)ethoxymethyl chloride (0.77 mL, 4.4 mmol). After 30 min, the reaction was poured into water (50 mL), the layers were separated, and the aqueous phase was extracted with ethyl acetate (2*50 mL). The organic layers were combined, washed with brine (30 mL), dried over magnesium sulfate, filtered and concentrated in vacuo to give 1, 3-dihydro-I-(2'-trimethylsilylethyl)-2, 1-benzisothiazoline 2,2-dioxide (1.3 g, 99%) as an off-white solid. 1H NMR (CDCl3, 300 MHz) delta0.02 (s, 9 H), 0.97 (dd, 2 H, J=8.3, 8.2 Hz), 3.73 (dd, 2 H, J=8.2, 8.3 Hz), 4.40 (s, 2 H), 5.08 (s, 2 H), 7.05 (d, 1 H, J=7.4 Hz), 7.07 (dd, 1 H), 7.26 (d, 1 H, J=7.4 Hz), 7.35 ('t', 1H, J=7.6, 7.6 Hz). MS ((+) APCI m/z 317 [M+NH4]+.

Reference： [1]Patent: US6339098,2002,B1 .Location in patent: Page column 14

39
[ 6961-82-6 ]
[ 111248-89-6 ]

Reference： [1]Patent: US6339098,2002,B1 .Location in patent: Page column 10

40
[ 111248-89-6 ]
[ 106-95-6 ]
C₁₀H₁₁NO₂S [ No CAS ]

Reference： [1]Patent: WO2005/63690,2005,A1 .Location in patent: Page/Page column 23

41
[ 3958-60-9 ]
[ 111248-89-6 ]

Reference： [1]Patent: WO2013/131408,2013,A1

42
[ 41345-06-6 ]
[ 111248-89-6 ]

Reference： [1]Patent: WO2013/131408,2013,A1

43
[ 111248-89-6 ]
[ 1455471-78-9 ]

Reference： [1]Patent: WO2013/131408,2013,A1

44
[ 111248-89-6 ]
[ 1455471-75-6 ]

Reference： [1]Patent: WO2013/131408,2013,A1

45
[ 111248-89-6 ]
[ 1455471-76-7 ]

Reference： [1]Patent: WO2013/131408,2013,A1

46
[ 111248-89-6 ]
[ 1455471-77-8 ]

Reference： [1]Patent: WO2013/131408,2013,A1

47
[ 24974-75-2 ]
[ 111248-89-6 ]

Yield	Reaction Conditions	Operation in experiment
6.5%		Preparation 17 1,3-Dihydrobenzo[c]isothiazole 2,2-dioxide The title compound was prepared using the method described in WO 98/32438 A1. To a solution of 2-nitro-alpha-toluenesulfonyl chloride (5.1 g, 21.6 mmol) in anhydrous ethyl acetate (250 mL) was added tin(II) chloride (19.3 g, 86 mmol). The reaction was stirred overnight at 70 C., then poured onto ice and neutralized with saturated aqueous sodium bicarbonate. The solution was filtered through Celite, extracted with ethyl acetate, and the organic layer concentrated. To the crude residue was added anhydrous methylene chloride (200 mL) and triethylamine (5 mL). The solution was stirred overnight at room temperature and concentrated under reduced pressure. The product was obtained by silica gel column chromatography (30-100% ethyl acetate in hexanes) followed by recrystallization from methylene chloride/hexanes to give a white solid. (0.24 g, 6.5%). 1H NMR (CDCl3, 300 MHz) delta 7.30-7.22 (m, 2H), 7.07-7.02 (t, 1H, J=7.4 Hz), 6.89-6.86 (dd, 1H, J=0.6, 8.1 Hz), 6.66 (br s, 1H), 4.39 (s, 1H).

Reference： [1]Patent: US2013/303524,2013,A1 .Location in patent: Paragraph 0270-0271

48
[ 77421-13-7 ]
[ 111248-89-6 ]

Reference： [1]Patent: WO2014/63778,2014,A1
[2]Patent: WO2015/144290,2015,A1
[3]Patent: US2016/16951,2016,A1
[4]Journal of Medicinal Chemistry,2016,vol. 59,p. 1078 - 1101

49
[ 111248-89-6 ]
rac-2'-amino-3'-chloro-3-hydroxy-5'-(1-methyl-2,2-dioxo-2,3-dihydro-1H-benzo[c]isothiazol-5-yl)-3,4,5,6-tetrahydro-2H-[1,4']bipyridinyl-4-carbonitrile [ No CAS ]

Reference： [1]Patent: WO2014/63778,2014,A1

50
[ 111248-89-6 ]
[ 1607837-66-0 ]

Reference： [1]Patent: WO2014/63778,2014,A1
[2]Journal of Medicinal Chemistry,2016,vol. 59,p. 1078 - 1101

51
[ 111248-89-6 ]
[ 1607837-67-1 ]

Reference： [1]Patent: WO2014/63778,2014,A1
[2]Journal of Medicinal Chemistry,2016,vol. 59,p. 1078 - 1101

52
[ 111248-89-6 ]
racemic trans-3'-chloro-3-hydroxy-2'-(4-methoxybenzylamino)-5'-(1-methyl-2,2-dioxo-2,3-dihydro-1H-benzo[c]isothiazol-5-yl)-3,4,5,6-tetrahydro-2H-[1,4']bipyridinyl-4-carbonitrile [ No CAS ]

Reference： [1]Patent: WO2014/63778,2014,A1

53
[ 111248-89-6 ]
[ 1607837-32-0 ]

Reference： [1]Patent: WO2014/63778,2014,A1
[2]Journal of Medicinal Chemistry,2016,vol. 59,p. 1078 - 1101

54
[ 111248-89-6 ]
[ 41713-63-7 ]

Reference： [1]Patent: WO2014/63778,2014,A1
[2]Patent: WO2015/144290,2015,A1
[3]Patent: US2016/16951,2016,A1
[4]Journal of Medicinal Chemistry,2016,vol. 59,p. 1078 - 1101

55
[ 111248-89-6 ]
[ 1607838-13-0 ]

Reference： [1]Patent: WO2014/63778,2014,A1
[2]Patent: WO2015/144290,2015,A1
[3]Patent: US2016/16951,2016,A1
[4]Journal of Medicinal Chemistry,2016,vol. 59,p. 1078 - 1101

56
[ 111248-89-6 ]
5'-chloro-4-(2-hydroxy-ethyl)-3'-(1-methyl-2,2-dioxo-2,3-dihydro-1H-benzo[c]isothiazol-5-yl)-3,4,5,6-tetrahydro-2H-[1,4']bipyridinyl-4-carbonitrile [ No CAS ]

Reference： [1]Patent: WO2015/144290,2015,A1

57
[ 111248-89-6 ]
8-[3-chloro-5-(1-methyl-2,2-dioxo-2,3-dihydro-1H-benzo[c]isothiazol-5-yl)-pyridin-4-yl]-4-ethyl-2,3,8-triazaspiro[4.5]dec-3-en-1-one [ No CAS ]

Reference： [1]Patent: WO2015/144290,2015,A1

58
[ 111248-89-6 ]
[ 1607838-33-4 ]

Reference： [1]Patent: WO2015/144290,2015,A1
[2]Patent: US2016/16951,2016,A1

59
[ 111248-89-6 ]
4-(2,2-dioxido-1,3-dihydrobenzo[c]isothiazol-5-yl)isoquinoline-6-carbonitrile [ No CAS ]

Reference： [1]Patent: US2016/16951,2016,A1

60
[ 111248-89-6 ]
azetidin-1-yl(4-(2,2-dioxido-1,3-dihydrobenzo[c]isothiazol-5-yl)isoquinolin-6-yl)methanone [ No CAS ]

Reference： [1]Patent: US2016/16951,2016,A1

61
[ 111248-89-6 ]
4-(2,2-dioxido-1,3-dihydrobenzo[c]isothiazol-5-yl)isoquinoline-6-carboxylic acid [ No CAS ]

Reference： [1]Patent: US2016/16951,2016,A1

62
[ 111248-89-6 ]
(1-amino-4-(2,2-dioxido-1,3-dihydrobenzo[c]isothiazol-5-yl)isoquinolin-6-yl)(azetidin-1-yl)methanone [ No CAS ]

Reference： [1]Patent: US2016/16951,2016,A1

63
[ 111248-89-6 ]
8-(1-methyl-2,2-dioxo-2,3-dihydro-1H-benzo[c]isothiazol-5-yl)-[1,6]naphthyridine-2-carboxylic acid methylamide [ No CAS ]

Reference： [1]Patent: US2016/16951,2016,A1

64
[ 111248-89-6 ]
(2-[8-(1-methyl-2,2-dioxo-2,3-dihydro-1H-benzo[c]isothiazol-5-yl)-[1,6]naphthyridine-2-carbonyl]amino}ethyl)carbamic acid tert-butyl ester [ No CAS ]

Reference： [1]Patent: US2016/16951,2016,A1

65
[ 111248-89-6 ]
(5-amino-8-(2,2-dioxido-1,3-dihydrobenzo[c]isothiazol-5-yl)-1,6-naphthyridin-2-yl)(3,3-difluoropyrrolidin-1-yl)methanone [ No CAS ]

Reference： [1]Patent: US2016/16951,2016,A1

66
[ 111248-89-6 ]
[8-(1-methyl-2,2-dioxo-2,3-dihydro-1H-benzo[c]isothiazol-5-yl)-[1,6]naphthyridin-2-yl]methanol [ No CAS ]

Reference： [1]Patent: US2016/16951,2016,A1

67
[ 111248-89-6 ]
8-(2,2-dioxido-1,3-dihydrobenzo[c]isothiazol-5-yl)-5-methoxy-1,6-naphthyridine-2-carbonitrile [ No CAS ]

Reference： [1]Patent: US2016/16951,2016,A1

68
[ 111248-89-6 ]
8-(2,2-dioxido-1,3-dihydrobenzo[c]isothiazol-5-yl)-5-methoxy-N-methyl-1,6-naphthyridine-2-carboxamide [ No CAS ]

Reference： [1]Patent: US2016/16951,2016,A1

69
[ 111248-89-6 ]
8-(2,2-dioxido-1,3-dihydrobenzo[c]isothiazol-5-yl)-5-hydroxy-N-methyl-1,6-naphthyridine-2-carboxamide [ No CAS ]

Reference： [1]Patent: US2016/16951,2016,A1

70
[ 111248-89-6 ]
1-methyl-5-(2-methyl-1,6-naphthyridin-8-yl)-1,3-dihydrobenzo[c]isothiazole-2,2-dioxide [ No CAS ]

Reference： [1]Patent: US2016/16951,2016,A1

71
[ 111248-89-6 ]
5-amino-8-(1-methyl-2,2-dioxo-2,3-dihydro-1H-benzo[c]isothiazol-5-yl)-[1,6]naphthyridine-2-carboxylic acid methylamide [ No CAS ]

Reference： [1]Patent: US2016/16951,2016,A1

72
[ 111248-89-6 ]
3-methyl-8-(1-methyl-2,2-dioxo-2,3-dihydro-1H-benzo[c]isothiazol-5-yl)-[1,6]naphthyridine-2-carboxylic acid methylamide trifluoracetate salt [ No CAS ]

Reference： [1]Patent: US2016/16951,2016,A1

73
[ 111248-89-6 ]
8-(2,2-dioxo-2,3-dihydro-1H-benzo[c]isothiazol-5-yl)-[1,6]naphthyridine-2-carboxylic acid (2-hydroxyethyl)methylamide hydrochloride [ No CAS ]

Reference： [1]Patent: US2016/16951,2016,A1

74
[ 111248-89-6 ]
8-(1-methyl-2,2-dioxo-2,3-dihydro-1H-benzo[c]isothiazol-5-yl)-[1,6]naphthyridine-2-carboxylic acid (2-aminoethyl)amide [ No CAS ]

Reference： [1]Patent: US2016/16951,2016,A1

75
[ 111248-89-6 ]
[8-(1-methyl-2,2-dioxo-2,3-dihydro-1H-benzo[c]isothiazol-5-yl)-6-oxy-[1,6]naphthyridin-2-yl]methanol [ No CAS ]

Reference： [1]Patent: US2016/16951,2016,A1

76
[ 111248-89-6 ]
[5-amino-8-(1-methyl-2,2-dioxo-2,3-dihydro-1H-benzo[c]isothiazol-5-yl)-[1,6]naphthyridin-2-yl]methanol trifluoroacetate salt [ No CAS ]

Reference： [1]Patent: US2016/16951,2016,A1

77
[ 111248-89-6 ]
2-chloromethyl-8-(1-methyl-2,2-dioxo-2,3-dihydro-1H-benzo[c]isothiazol-5-yl)-[1,6]naphthyridine [ No CAS ]

Reference： [1]Patent: US2016/16951,2016,A1

78
[ 111248-89-6 ]
C-[8-(1-methyl-2,2-dioxo-2,3-dihydro-1H-benzo[c]isothiazol-5-yl)-[1,6]naphthyridin-2-yl]methylamine [ No CAS ]

Reference： [1]Patent: US2016/16951,2016,A1

79
[ 111248-89-6 ]
N-[8-(1-methyl-2,2-dioxo-2,3-dihydro-1H-benzo[c]isothiazol-5-yl)-[1,6]naphthyridin-2-ylmethyl]-acetamide trifluoracetate salt [ No CAS ]

Reference： [1]Patent: US2016/16951,2016,A1

80
[ 111248-89-6 ]
8-[3-chloro-5-(1-methyl-2,2-dioxo-2,3-dihydro-1H-216-benzo[c]isothiazol-5-yl)-pyridin-4-yl]-1,3,8-triazaspiro[4.5]decane-2,4-dione [ No CAS ]

Reference： [1]Journal of Medicinal Chemistry,2016,vol. 59,p. 1078 - 1101

81
[ 111248-89-6 ]
8-[3-chloro-5-(1-methyl-2,2-dioxo-2,3-dihydro-1H-216-benzo[c]isothiazol-5-yl)-pyridin-4-yl]-2-methyl-1,3,8-triaza-spiro[4.5]dec-1-en-4-one [ No CAS ]

Reference： [1]Journal of Medicinal Chemistry,2016,vol. 59,p. 1078 - 1101

82
[ 111248-89-6 ]
8-[3-chloro-5-(1-methyl-2,2-dioxo-2,3-dihydro-1H-benzo[c]isothiazol-5-yl)-pyridin-4-yl]-4-methyl-2,3,8-triazaspiro[4.5]dec-3-en-1-one [ No CAS ]

Reference： [1]Journal of Medicinal Chemistry,2016,vol. 59,p. 1078 - 1101

83
[ 111248-89-6 ]
8-[3-chloro-5-(1-methyl-2,2-dioxo-2,3-dihydro-1H-benzo[c]isothiazol-5-yl)-pyridin-4-yl]-4-trifluoromethyl-2,3,8-triazaspiro[4.5]dec-3-en-1-one [ No CAS ]

Reference： [1]Journal of Medicinal Chemistry,2016,vol. 59,p. 1078 - 1101

84
[ 111248-89-6 ]
1-(3-chloro-5-(1-methyl-2,2-dioxido-1,3-dihydrobenzo[c]isothiazol-5-yl)pyridin-4-yl)-4-(2-(dimethylamino)ethyl)piperidine-4-carbonitrile [ No CAS ]

Reference： [1]Journal of Medicinal Chemistry,2016,vol. 59,p. 1078 - 1101

85
[ 111248-89-6 ]
5-(5-chloro-4-(1-methyl-1,8-diazaspiro[4.5]decan-8-yl)pyridin-3-yl)-1-methyl-1,3-dihydrobenzo[c]isothiazole 2,2-dioxide [ No CAS ]

Reference： [1]Journal of Medicinal Chemistry,2016,vol. 59,p. 1078 - 1101

86
[ 111248-89-6 ]
8-[3-chloro-5-(1-methyl-2,2-dioxo-2,3-dihydro-1H-2l6-benzo[c]isothiazol-5-yl)-pyridin-4-yl]-1-oxa-3,8-diaza-spiro[4.5]decan-2-one [ No CAS ]

Reference： [1]Journal of Medicinal Chemistry,2016,vol. 59,p. 1078 - 1101

87
[ 111248-89-6 ]
5-(5-chloro-4-(1-(2-methoxyethyl)-1,8-diazaspiro[4.5]decan-8-yl)pyridin-3-yl)-1-methyl-1,3-dihydrobenzo[c]-isothiazole 2,2-dioxide [ No CAS ]

Reference： [1]Journal of Medicinal Chemistry,2016,vol. 59,p. 1078 - 1101

88
[ 111248-89-6 ]
5-(5-chloro-4-(1-(3-methoxypropyl)-1,8-diazaspiro[4.5]decan-8-yl)pyridin-3-yl)-1-methyl-1,3-dihydrobenzo[c]isothiazole 2,2-dioxide [ No CAS ]

Reference： [1]Journal of Medicinal Chemistry,2016,vol. 59,p. 1078 - 1101

Same Skeleton Products

Related Products

Historical Records

Related Functional Groups of
[ 111248-89-6 ]

Sulfamides

[ 603-72-5 ]

2H-Naphtho[1,8-cd]isothiazole 1,1-dioxide

Similarity: 0.81

[ 109903-35-7 ]

4-Amino-N-methylbenzenemethanesulfonamide

Similarity: 0.79

[ 4703-15-5 ]

N-(2,6-dimethylphenyl)-4-methylbenzenesulfonamide

Similarity: 0.74

[ 88933-16-8 ]

1-(4-Hydrazinylphenyl)-N-methylmethanesulfonamide hydrochloride

Similarity: 0.72

[ 334981-11-2 ]

1-((4-Hydrazinylbenzyl)sulfonyl)pyrrolidine hydrochloride

Similarity: 0.71

Ghs Precautionary Statements

Precautionary Statements-General
Code	Phrase
P101	If medical advice is needed,have product container or label at hand.
P102	Keep out of reach of children.
P103	Read label before use
Prevention
Code	Phrase
P201	Obtain special instructions before use.
P202	Do not handle until all safety precautions have been read and understood.
P210	Keep away from heat/sparks/open flames/hot surfaces. - No smoking.
P211	Do not spray on an open flame or other ignition source.
P220	Keep/Store away from clothing/combustible materials.
P221	Take any precaution to avoid mixing with combustibles
P222	Do not allow contact with air.
P223	Keep away from any possible contact with water, because of violent reaction and possible flash fire.
P230	Keep wetted
P231	Handle under inert gas.
P232	Protect from moisture.
P233	Keep container tightly closed.
P234	Keep only in original container.
P235	Keep cool
P240	Ground/bond container and receiving equipment.
P241	Use explosion-proof electrical/ventilating/lighting/equipment.
P242	Use only non-sparking tools.
P243	Take precautionary measures against static discharge.
P244	Keep reduction valves free from grease and oil.
P250	Do not subject to grinding/shock/friction.
P251	Pressurized container: Do not pierce or burn, even after use.
P260	Do not breathe dust/fume/gas/mist/vapours/spray.
P261	Avoid breathing dust/fume/gas/mist/vapours/spray.
P262	Do not get in eyes, on skin, or on clothing.
P263	Avoid contact during pregnancy/while nursing.
P264	Wash hands thoroughly after handling.
P265	Wash skin thouroughly after handling.
P270	Do not eat, drink or smoke when using this product.
P271	Use only outdoors or in a well-ventilated area.
P272	Contaminated work clothing should not be allowed out of the workplace.
P273	Avoid release to the environment.
P280	Wear protective gloves/protective clothing/eye protection/face protection.
P281	Use personal protective equipment as required.
P282	Wear cold insulating gloves/face shield/eye protection.
P283	Wear fire/flame resistant/retardant clothing.
P284	Wear respiratory protection.
P285	In case of inadequate ventilation wear respiratory protection.
P231 + P232	Handle under inert gas. Protect from moisture.
P235 + P410	Keep cool. Protect from sunlight.
Response
Code	Phrase
P301	IF SWALLOWED:
P304	IF INHALED:
P305	IF IN EYES:
P306	IF ON CLOTHING:
P307	IF exposed:
P308	IF exposed or concerned:
P309	IF exposed or if you feel unwell:
P310	Immediately call a POISON CENTER or doctor/physician.
P311	Call a POISON CENTER or doctor/physician.
P312	Call a POISON CENTER or doctor/physician if you feel unwell.
P313	Get medical advice/attention.
P314	Get medical advice/attention if you feel unwell.
P315	Get immediate medical advice/attention.
P320
P302 + P352	IF ON SKIN: wash with plenty of soap and water.
P321
P322
P330	Rinse mouth.
P331	Do NOT induce vomiting.
P332	IF SKIN irritation occurs:
P333	If skin irritation or rash occurs:
P334	Immerse in cool water/wrap n wet bandages.
P335	Brush off loose particles from skin.
P336	Thaw frosted parts with lukewarm water. Do not rub affected area.
P337	If eye irritation persists:
P338	Remove contact lenses, if present and easy to do. Continue rinsing.
P340	Remove victim to fresh air and keep at rest in a position comfortable for breathing.
P341	If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing.
P342	If experiencing respiratory symptoms:
P350	Gently wash with plenty of soap and water.
P351	Rinse cautiously with water for several minutes.
P352	Wash with plenty of soap and water.
P353	Rinse skin with water/shower.
P360	Rinse immediately contaminated clothing and skin with plenty of water before removing clothes.
P361	Remove/Take off immediately all contaminated clothing.
P362	Take off contaminated clothing and wash before reuse.
P363	Wash contaminated clothing before reuse.
P370	In case of fire:
P371	In case of major fire and large quantities:
P372	Explosion risk in case of fire.
P373	DO NOT fight fire when fire reaches explosives.
P374	Fight fire with normal precautions from a reasonable distance.
P376	Stop leak if safe to do so. Oxidising gases (section 2.4) 1
P377	Leaking gas fire: Do not extinguish, unless leak can be stopped safely.
P378
P380	Evacuate area.
P381	Eliminate all ignition sources if safe to do so.
P390	Absorb spillage to prevent material damage.
P391	Collect spillage. Hazardous to the aquatic environment
P301 + P310	IF SWALLOWED: Immediately call a POISON CENTER or doctor/physician.
P301 + P312	IF SWALLOWED: call a POISON CENTER or doctor/physician IF you feel unwell.
P301 + P330 + P331	IF SWALLOWED: Rinse mouth. Do NOT induce vomiting.
P302 + P334	IF ON SKIN: Immerse in cool water/wrap in wet bandages.
P302 + P350	IF ON SKIN: Gently wash with plenty of soap and water.
P303 + P361 + P353	IF ON SKIN (or hair): Remove/Take off Immediately all contaminated clothing. Rinse SKIN with water/shower.
P304 + P312	IF INHALED: Call a POISON CENTER or doctor/physician if you feel unwell.
P304 + P340	IF INHALED: Remove victim to fresh air and Keep at rest in a position comfortable for breathing.
P304 + P341	IF INHALED: If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing.
P305 + P351 + P338	IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.
P306 + P360	IF ON CLOTHING: Rinse Immediately contaminated CLOTHING and SKIN with plenty of water before removing clothes.
P307 + P311	IF exposed: call a POISON CENTER or doctor/physician.
P308 + P313	IF exposed or concerned: Get medical advice/attention.
P309 + P311	IF exposed or if you feel unwell: call a POISON CENTER or doctor/physician.
P332 + P313	IF SKIN irritation occurs: Get medical advice/attention.
P333 + P313	IF SKIN irritation or rash occurs: Get medical advice/attention.
P335 + P334	Brush off loose particles from skin. Immerse in cool water/wrap in wet bandages.
P337 + P313	IF eye irritation persists: Get medical advice/attention.
P342 + P311	IF experiencing respiratory symptoms: call a POISON CENTER or doctor/physician.
P370 + P376	In case of fire: Stop leak if safe to Do so.
P370 + P378	In case of fire:
P370 + P380	In case of fire: Evacuate area.
P370 + P380 + P375	In case of fire: Evacuate area. Fight fire remotely due to the risk of explosion.
P371 + P380 + P375	In case of major fire and large quantities: Evacuate area. Fight fire remotely due to the risk of explosion.
Storage
Code	Phrase
P401
P402	Store in a dry place.
P403	Store in a well-ventilated place.
P404	Store in a closed container.
P405	Store locked up.
P406	Store in corrosive resistant/ container with a resistant inner liner.
P407	Maintain air gap between stacks/pallets.
P410	Protect from sunlight.
P411
P412	Do not expose to temperatures exceeding 50 oC/ 122 oF.
P413
P420	Store away from other materials.
P422
P402 + P404	Store in a dry place. Store in a closed container.
P403 + P233	Store in a well-ventilated place. Keep container tightly closed.
P403 + P235	Store in a well-ventilated place. Keep cool.
P410 + P403	Protect from sunlight. Store in a well-ventilated place.
P410 + P412	Protect from sunlight. Do not expose to temperatures exceeding 50 oC/122oF.
P411 + P235	Keep cool.
Disposal
Code	Phrase
P501	Dispose of contents/container to ...
P502	Refer to manufacturer/supplier for information on recovery/recycling

Purity	Size	Price	VIP Price	USA Stock *0-1 Day	Global Stock *5-7 Days	Quantity
{[ item.p_purity ]}	{[ item.pr_size ]}	{[ getRatePrice(item.pr_usd, 1,1) ]} {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]}	{[ getRatePrice(item.pr_usd, 1,1) ]}	Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_usd,1,item.mem_rate) ]}	{[ item.pr_usastock ]}	Inquiry -	{[ item.pr_chinastock ]}	Inquiry -

Physical hazards
Code	Phrase
H200	Unstable explosive
H201	Explosive; mass explosion hazard
H202	Explosive; severe projection hazard
H203	Explosive; fire, blast or projection hazard
H204	Fire or projection hazard
H205	May mass explode in fire
H220	Extremely flammable gas
H221	Flammable gas
H222	Extremely flammable aerosol
H223	Flammable aerosol
H224	Extremely flammable liquid and vapour
H225	Highly flammable liquid and vapour
H226	Flammable liquid and vapour
H227	Combustible liquid
H228	Flammable solid
H229	Pressurized container: may burst if heated
H230	May react explosively even in the absence of air
H231	May react explosively even in the absence of air at elevated pressure and/or temperature
H240	Heating may cause an explosion
H241	Heating may cause a fire or explosion
H242	Heating may cause a fire
H250	Catches fire spontaneously if exposed to air
H251	Self-heating; may catch fire
H252	Self-heating in large quantities; may catch fire
H260	In contact with water releases flammable gases which may ignite spontaneously
H261	In contact with water releases flammable gas
H270	May cause or intensify fire; oxidizer
H271	May cause fire or explosion; strong oxidizer
H272	May intensify fire; oxidizer
H280	Contains gas under pressure; may explode if heated
H281	Contains refrigerated gas; may cause cryogenic burns or injury
H290	May be corrosive to metals
Health hazards
Code	Phrase
H300	Fatal if swallowed
H301	Toxic if swallowed
H302	Harmful if swallowed
H303	May be harmful if swallowed
H304	May be fatal if swallowed and enters airways
H305	May be harmful if swallowed and enters airways
H310	Fatal in contact with skin
H311	Toxic in contact with skin
H312	Harmful in contact with skin
H313	May be harmful in contact with skin
H314	Causes severe skin burns and eye damage
H315	Causes skin irritation
H316	Causes mild skin irritation
H317	May cause an allergic skin reaction
H318	Causes serious eye damage
H319	Causes serious eye irritation
H320	Causes eye irritation
H330	Fatal if inhaled
H331	Toxic if inhaled
H332	Harmful if inhaled
H333	May be harmful if inhaled
H334	May cause allergy or asthma symptoms or breathing difficulties if inhaled
H335	May cause respiratory irritation
H336	May cause drowsiness or dizziness
H340	May cause genetic defects
H341	Suspected of causing genetic defects
H350	May cause cancer
H351	Suspected of causing cancer
H360	May damage fertility or the unborn child
H361	Suspected of damaging fertility or the unborn child
H361d	Suspected of damaging the unborn child
H362	May cause harm to breast-fed children
H370	Causes damage to organs
H371	May cause damage to organs
H372	Causes damage to organs through prolonged or repeated exposure
H373	May cause damage to organs through prolonged or repeated exposure
Environmental hazards
Code	Phrase
H400	Very toxic to aquatic life
H401	Toxic to aquatic life
H402	Harmful to aquatic life
H410	Very toxic to aquatic life with long-lasting effects
H411	Toxic to aquatic life with long-lasting effects
H412	Harmful to aquatic life with long-lasting effects
H413	May cause long-lasting harmful effects to aquatic life
H420	Harms public health and the environment by destroying ozone in the upper atmosphere

[ CAS No. 111248-89-6 ] {[proInfo.proName]}

Quality Control of [ 111248-89-6 ]

Related Doc. of [ 111248-89-6 ]

Product Details of [ 111248-89-6 ]

Calculated chemistry of [ 111248-89-6 ]

Physicochemical Properties

Pharmacokinetics

Lipophilicity

Druglikeness

Water Solubility

Medicinal Chemistry

Safety of [ 111248-89-6 ]

Application In Synthesis of [ 111248-89-6 ]

[ 111248-89-6 ] Synthesis Path-Upstream 1~8

[ 111248-89-6 ] Synthesis Path-Downstream 1~88

Related Functional Groups of [ 111248-89-6 ]

Sulfamides

Precautionary Statements-General

Prevention

Response

Storage

Disposal

Physical hazards

Health hazards

Environmental hazards

Inquiry

Related Functional Groups of
[ 111248-89-6 ]